Cargando…

Publisher Correction to: Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies

Detalles Bibliográficos
Autores principales:	Koga, Shunsuke, Murakami, Aya, Soto-Beasley, Alexandra I., Walton, Ronald L., Baker, Matthew C., Castanedes-Casey, Monica, Josephs, Keith A., Ross, Owen A., Dickson, Dennis W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Publisher Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339526/ https://www.ncbi.nlm.nih.gov/pubmed/37438786 http://dx.doi.org/10.1186/s40478-023-01621-x

Ejemplares similares

Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
por: Koga, Shunsuke, et al.
Publicado: (2023)

Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
por: Pickles, Sarah, et al.
Publicado: (2022)

TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP
por: Arseni, Diana, et al.
Publicado: (2023)

Molecular Neuropathology of TDP-43 Proteinopathies
por: Neumann, Manuela
Publicado: (2009)

Mechanisms and models of TDP-43 proteinopathies
por: Petrucelli, Leonard
Publicado: (2012)

Drosophila Answers to TDP-43 Proteinopathies
por: Romano, Maurizio, et al.
Publicado: (2012)

Rodent Models of TDP-43 Proteinopathy: Investigating the Mechanisms of TDP-43-Mediated Neurodegeneration
por: Gendron, Tania F., et al.
Publicado: (2011)

C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation
por: Josephs, Keith A., et al.
Publicado: (2019)

TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy
por: Atkinson, Rachel, et al.
Publicado: (2021)

TDP-43 Pathology in Alzheimer’s Disease
por: Meneses, Axel, et al.
Publicado: (2021)

The basis of clinicopathological heterogeneity in TDP-43 proteinopathy
por: Kawakami, Ito, et al.
Publicado: (2019)

Mechanisms of TDP-43 Proteinopathy Onset and Propagation
por: Chen, Han-Jou, et al.
Publicado: (2021)

Propagation of TDP-43 proteinopathy in neurodegenerative disorders
por: Keszycki, Rachel, et al.
Publicado: (2021)

TDP-43 Proteinopathy Specific Biomarker Development
por: Cordts, Isabell, et al.
Publicado: (2023)

Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD–TDP subtypes
por: Neumann, Manuela, et al.
Publicado: (2020)

TDP-43 proteinopathies: a new wave of neurodegenerative diseases
por: de Boer, Eva Maria Johanna, et al.
Publicado: (2021)

Microglial lysosome dysfunction contributes to white matter pathology and TDP-43 proteinopathy in GRN-associated FTD
por: Wu, Yanwei, et al.
Publicado: (2021)

Mitochondrion-Dependent Cell Death in TDP-43 Proteinopathies
por: Lucini, Chantal B., et al.
Publicado: (2021)

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy
por: Necarsulmer, Julie C, et al.
Publicado: (2023)

Facial Onset Sensory and Motor Neuronopathy: Further Evidence for a TDP-43 Proteinopathy
por: Ziso, Besa, et al.
Publicado: (2015)

Neuropathological potential of FUS and TDP-43 in flies
Publicado: (2011)

Towards a TDP-43-Based Biomarker for ALS and FTLD
por: Feneberg, Emily, et al.
Publicado: (2018)

The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
por: Berning, Britt A., et al.
Publicado: (2019)

Old age amyotrophic lateral sclerosis and limbic TDP‐43 pathology
por: Murakami, Aya, et al.
Publicado: (2022)

Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
por: Fiondella, Luigi, et al.
Publicado: (2023)

Disease Animal Models of TDP-43 Proteinopathy and Their Pre-Clinical Applications
por: Liu, Yu-Chih, et al.
Publicado: (2013)

TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
por: Scotter, Emma L., et al.
Publicado: (2015)

Lipid alterations in human frontal cortex in ALS‐FTLD‐TDP43 proteinopathy spectrum are partly related to peroxisome impairment
por: Andrés‐Benito, Pol, et al.
Publicado: (2021)

Neuronal overexpression of hTDP-43 in Caenorhabditis elegans mimics the cellular pathology commonly observed in TDP-43 proteinopathies
por: Koopman, Mandy, et al.
Publicado: (2023)

TDP-43 proteinopathy in Theiler’s murine encephalomyelitis virus infection
por: Masaki, Katsuhisa, et al.
Publicado: (2019)

Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency
por: Zhang, Jiasheng, et al.
Publicado: (2020)

Functional implication of ubiquitinating and deubiquitinating mechanisms in TDP-43 proteinopathies
por: Tran, Non-Nuoc, et al.
Publicado: (2022)

TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?
por: Riku, Yuichi, et al.
Publicado: (2022)

Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies
por: Young, Alexandra L, et al.
Publicado: (2023)

Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies
por: Cheng, Hei W. A., et al.
Publicado: (2022)

Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies
por: Young, Alexandra L, et al.
Publicado: (2023)

Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS
por: Chang, Cheng-Fu, et al.
Publicado: (2016)

Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD
por: Tamaki, Yoshitaka, et al.
Publicado: (2022)

Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy
por: Matsukawa, Koji, et al.
Publicado: (2021)

FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases
por: Rusina, Robert, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_uih0vbn7mt0vl2mjohuohq0ai7